Deep-pocketed investors have adopted a bearish approach towards Madrigal Pharmaceuticals MDGL, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MDGL usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 24 extraordinary options activities for Madrigal Pharmaceuticals. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 15 are puts, totaling $931,690, and 9 are calls, amounting to $1,430,410.
Predicted Price Range
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $140.0 and $260.0 for Madrigal Pharmaceuticals, spanning the last three months.
Volume & Open Interest Trends
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Madrigal Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Madrigal Pharmaceuticals's significant trades, within a strike price range of $140.0 to $260.0, over the past month.
Madrigal Pharmaceuticals 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MDGL | CALL | TRADE | BEARISH | 01/17/25 | $210.00 | $480.0K | 2.7K | 301 |
| MDGL | CALL | TRADE | BEARISH | 01/17/25 | $210.00 | $418.0K | 2.7K | 101 |
| MDGL | CALL | TRADE | BEARISH | 01/17/25 | $210.00 | $200.0K | 2.7K | 181 |
| MDGL | PUT | SWEEP | BEARISH | 04/19/24 | $140.00 | $164.0K | 3 | 300 |
| MDGL | PUT | SWEEP | BEARISH | 04/19/24 | $140.00 | $163.9K | 3 | 200 |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Following our analysis of the options activities associated with Madrigal Pharmaceuticals, we pivot to a closer look at the company's own performance.
Current Position of Madrigal Pharmaceuticals
- Currently trading with a volume of 698,777, the MDGL's price is up by 0.77%, now at $190.0.
- RSI readings suggest the stock is currently may be oversold.
- Anticipated earnings release is in 14 days.
Professional Analyst Ratings for Madrigal Pharmaceuticals
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $336.0.
- An analyst from Piper Sandler has decided to maintain their Overweight rating on Madrigal Pharmaceuticals, which currently sits at a price target of $336.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Madrigal Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
